App-Quantinova.ai

Quality of Life in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice across Canada: Results from the Devote Study

Andrew Aw - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic Lymphocytic Leukemia

Venetoclax

Prolonged Maintenance of Ex Vivo Functional Vk*MYC Multiple Myeloma Cells Allows for in Vitro Manipulation and Subsequent In Vivo Analysis

Frances E Lock - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary plasma cell leukemia

N/A

CO43923: A Platform Study Evaluating the Safety and Efficacy of Multiple Treatment Combinations in Patients with Multiple Myeloma

Semira Sheikh - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Lenalidomide

G-CSF Use in Mobilization and Post-Hematopoietic Stem Cell Transplant Induces Regulatory Myeloid Populations

Erika McCartney - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Plerixafor

Predicting Response of CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL) in ACIT001/EXC002, a Phase Ib Clinical Trial

Bindu Thapa - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

Interferon Gamma

Early Collected Leukapheresis Material Improves Tisagenlecleucel Manufacturing Success and Time from Order to Pickup of the Leukapheresis Product: A Real-World Experience

Tina Smrekar - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

tisagenlecleucel-t

Influence of Conditioning Regimen Intensity on Outcomes Post-Allogeneic Transplantation for AML in Complete Morphological Remission

Tommy Alfaro - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

fludarabine tablet

Circulating Cell Free Mitochondrial DNA As a Diagnostic and Prognostic Biomarker in Chronic and Late Acute Graft-Versus-Host Disease in Children

Shima Azadpour - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

N/A

A Retrospective Cohort Study of Donor Cell Leukemia

Brittany Salter - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Brenda W. Cooper - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute myelocytic leukemia

Gemtuzumab ozogamicin

Ex Vivo CRISPR-Based Sickle Cell Modeling

Yelena Boccacci - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Seth J Welsh - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Pomalidomide

Ex-Vivo Testing Using Patient Micro Avatars (PMAs) Predicts Clinical Response in Acute Leukemias

Alejandra Garcia - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

A Retrospective Analysis of Thromboprophylaxis in Hospitalized Patients with Cancer

Alex Dipierdomenico - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hematological malignancies

N/A

Anything but Cookbook Medicine: Exploring the Influence of Supervisor Practice Variability on Resident Learning in Thrombosis Medicine

Shahzaib Khattak - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

Clinical Impact and Outcomes of Socioeconomic Status on Patients with Sickle Cell Disease: A Pilot Study and Literature Review

Derman Ozdemir - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

Challenges in Treatment Decisions and Patient-Provider Communication in Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Nirav N. Shah - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

N/A

Development of the Autonomous Nurse Practitioner Role in an Outpatient Malignant Hematology Unit a Twenty-Year Odyssey

Suzanne Rowland - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Myelodysplastic Syndrome

N/A

Face Validity of the Kid's ITP Tools (KIT) in the Era of Thrombopoietin Receptor Agonists (TPO-RAs)

Catherine McGuire - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

The Canadian Registry for Amyloidosis Research: A National Multi-Disciplinary Registry for Real-World Evidence

Christopher P. Venner - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Amyloid disease

N/A

Filters

28841 Abstracts